ovarian-cancer

Documents about ovarian-cancer

• A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer#881560ClinicalTrials.gov
• Early Dehiscence Markers in Ovarian Cancer Surgery#804145ClinicalTrials.gov
• Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma.#812440ClinicalTrials.gov
• Clinical Benefit of Topoisomerase Downregulation#868578ClinicalTrials.gov
• Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer#238130ClinicalTrials.gov
• Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)#366596ClinicalTrials.gov
• Study Looking at Biomarkers in Ovarian Cancer#813738ClinicalTrials.gov
• Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes#837876ClinicalTrials.gov
• PITCH - Impacting Hereditary Cancer Testing#849289ClinicalTrials.gov
• Pillars4Life Trial#806478ClinicalTrials.gov
• Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer#803298ClinicalTrials.gov
• Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer#827996ClinicalTrials.gov
• AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer#813836ClinicalTrials.gov
• Differences in overall survival for invasive epithelial ovarian cancer by race and ethnicity: results from the Ovarian Cancer Association Consortium#928588Springer Nature OA
• Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers#837064ClinicalTrials.gov
• Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#353274ClinicalTrials.gov
• A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors#804570ClinicalTrials.gov
• Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer#836505ClinicalTrials.gov
• Improving ovarian cancer risk assessment using a machine learning model developed on data from the Prostate Lung Colorectal Ovarian Cancer Screening Trial.#421253NCBI PubMed Central
• Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.#802776ClinicalTrials.gov
• Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making#828203ClinicalTrials.gov
• Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection#840021ClinicalTrials.gov
• Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer#867474ClinicalTrials.gov
• The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients#887292ClinicalTrials.gov
• A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer#906120ClinicalTrials.gov
• A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)#906774ClinicalTrials.gov
• Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response#848731ClinicalTrials.gov
• Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies#245524ClinicalTrials.gov
• Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer#879577ClinicalTrials.gov
• Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring#906511ClinicalTrials.gov
• Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies#910820ClinicalTrials.gov
• Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer#911638ClinicalTrials.gov
• CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors#369864ClinicalTrials.gov
• Assessment of Ovarian Reserve in Female Cancer Survivors#877391ClinicalTrials.gov
• GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient#910177ClinicalTrials.gov
• Prognostic biomarkers in ovarian cancer#129210PMC Full-Text (OAI)
• Ovarian Cancer: Latest Advances and Prospects#354186HAL (France)
• Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer#146250ClinicalTrials.gov
• p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer#311182ClinicalTrials.gov
• RNAseq of NK cells from patients with ovarian cancer#437545Repositório de Dados de Pesquisa da Unicamp Dataverse OAI Archive
• Investigating nuclear import inhibition in combination with conventional chemotherapies, Paclitaxel or Topotecan, as novel therapeutic strategies for cervical and ovarian cancers#636974OpenUCT
• Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer#825651ClinicalTrials.gov
• Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers#845022ClinicalTrials.gov
• Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer#862422ClinicalTrials.gov
• Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer#884814ClinicalTrials.gov
• Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer#889441ClinicalTrials.gov
• Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment#894789ClinicalTrials.gov
• Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer#900199ClinicalTrials.gov
• A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers#861801ClinicalTrials.gov
• CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer#267998ClinicalTrials.gov